

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Lantuejoul 1



| Section 1. Identifying Inform  | ation                             |                        |             |                                  |           |
|--|-----------------------------------|------------------------|-------------|----------------------------------|-----------|
| Given Name (First Name)  Sylvie  | 2. Surname (Last Na<br>Lantuejoul | ime)                   |             | 3. Date<br>19-March-2020         |           |
| 4. Are you the corresponding author?   | ✓ Yes No                          |                        |             |                                  |           |
| 5. Manuscript Title<br>Selected highlights of the 2019 Pulmona   | ary Pathology Socie               | ty Biennial Meetir     | ng: PD-L1 t | est harmonization studies        |           |
| 6. Manuscript Identifying Number (if you kn<br>TLCR-2019-PPS-08(TLCR-20-145A)  | ow it)                            |                        |             |                                  |           |
|  |                                   |                        |             |                                  |           |
| Section 2. The Work Under Co   | onsideration for I                | Publication            |             |                                  |           |
| Did you or your institution <b>at any time</b> received any aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere | but not limited to gra            |                        |             |                                  |           |
| If yes, please fill out the appropriate info   | rmation below. If y               |                        | n one entit | y press the "ADD" button to ac   | dd a row. |
| Excess rows can be removed by pressing   | g the "X" button.                 |                        |             |                                  |           |
| Name of Institution/Company  | Grant? Persona Fees?              | Non-Financial Support? | Other?      | Comments                         |           |
| Astra Zeneca   |                                   |                        |             |                                  |           |
| MSD  |                                   |                        |             |                                  |           |
| BMS  | <b>✓</b>                          |                        |             |                                  |           |
|  |                                   |                        |             |                                  |           |
|  |                                   |                        |             |                                  |           |
| Section 3. Relevant financial a  | activities outside                | the submitted          | work.       |                                  |           |
| Place a check in the appropriate boxes in of compensation) with entities as describuling the "Add +" box. You should rep   | bed in the instruction            | ons. Use one line f    | or each en  | tity; add as many lines as you r | need by   |
| Are there any relevant conflicts of intere   |                                   | No                     |             |                                  |           |
| If yes, please fill out the appropriate info   | rmation below.                    |                        |             |                                  |           |
| Name of Entity   | Grant? Persona                    | Non-Financial          | Other?      | Comments                         |           |
| Abbvie   |                                   |                        |             |                                  |           |

Lantuejoul 2



| Section 4. Intellectual Property Patents & Copyrights  |
|--|
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes V No  |
| Section 5. Relationships not covered above   |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Lantuejoul reports personal fees from Astra Zeneca, personal fees from MSD, grants and personal fees from BMS, during the conduct of the study; personal fees from Abbvie, outside the submitted work; .                         |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Lantuejoul 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Damiola 1



| Section 1.                                   | Identifying Inform                             | nation  |  |
|--|--|---|--|
| 1. Given Name (Fi<br>Francesca               | rst Name)                                      | 2. Surname (Last Name)<br>Damiola                           | 3. Date<br>18-March-2020   |
| 4. Are you the cor                           | responding author?                             | Yes ✓ No  | Corresponding Author's Name<br>Sylvie Lantuejoul   |
| 5. Manuscript Title<br>Selected highlig      |  | nary Pathology Society Bie                                  | nnial Meeting: PD-L1 test harmonization studies  |
| -  | ntifying Number (if you kr<br>08(TLCR-20-145A) | now it)   |  |
|  |  |   | _  |
| Section 2.                                   | The Work Under Co                              | onsideration for Public                                     | cation   |
| any aspect of the s<br>statistical analysis, | ubmitted work (including                       | g but not limited to grants, da                             | a third party (government, commercial, private foundation, etc.) for at a monitoring board, study design, manuscript preparation,  |
| Section 3.                                   | Relevant financial                             | activities outside the s                                    | submitted work.  |
| of compensation clicking the "Add            | n) with entities as descri                     | ibed in the instructions. Us<br>port relationships that wer | ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication. |
| Section 4.                                   | Intellectual Duamen                            | utu. Datanta e Canani                                       | uhaa   |
|  | intellectual Proper                            | rty Patents & Copyric                                       | gnts ———   |
| Do you have any                              | patents, whether plan                          | ned, pending or issued, br                                  | roadly relevant to the work? Yes V No  |

Damiola 2



| Section 5. Polationships not severed above   |
|--|
| Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Damiola has nothing to disclose.   |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Damiola 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Adam 1



| Sortion 1   |                                 |   |                                     |  |
|---|---------------------------------|---|-------------------------------------|--|
| Section 1. Identifying Inform   | nation                          |   |                                     |  |
| 1. Given Name (First Name)<br>Julien  | 2. Surname (Last Name)<br>Adam  |   | 3. Date<br>18-March-2020            |  |
| 4. Are you the corresponding author?  | ☐ Yes ✓ No                      | Corresponding Author's Name Sylvie Lantuejoul |                                     |  |
| 5. Manuscript Title<br>Selected highlights of the 2019 Pulmor   | nary Pathology Society Bie      | nnial Meeting: PD-L1 test                     | harmonization studies               |  |
| 6. Manuscript Identifying Number (if you k<br>TLCR-2019-PPS-08(TLCR-20-145A)  | now it)                         | _   |                                     |  |
| Coation 2   |                                 |   |                                     |  |
| Section 2. The Work Under C   | onsideration for Public         | cation  |                                     |  |
| Did you or your institution <b>at any time</b> rece<br>any aspect of the submitted work (including<br>statistical analysis, etc.)?<br>Are there any relevant conflicts of inter | g but not limited to grants, da |   |                                     |  |
| If yes, please fill out the appropriate inf<br>Excess rows can be removed by pressir  |                                 | e more than one entity pr                     | ress the "ADD" button to add a row. |  |
| Name of Institution/Company   | Grant                           | n-Financial upport? Other? Co                 | omments                             |  |
| BMS   |                                 |   |                                     |  |
| MSD   | <b>✓</b>                        |   |                                     |  |
| AstraZeneca   |                                 |   |                                     |  |
| Roche   |                                 |   |                                     |  |
|   |                                 |   |                                     |  |
|   |                                 |   |                                     |  |
| Section 3. Relevant financial   | activities outside the          | submitted work.                               |                                     |  |
| Place a check in the appropriate boxes of compensation) with entities as describing the "Add +" box. You should re  | ibed in the instructions. Us    | se one line for each entity;                  | add as many lines as you need by    |  |
| Are there any relevant conflicts of inter   | •                               | c present during the 30                       | months prior to publication.        |  |

Adam 2



| Section 4. Intellectual Property Patents & Copyrights  |
|--|
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo  |
| Section 5.  Relationships not covered above  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?  |
| Yes, the following relationships/conditions/circumstances are present (explain below):   |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.  |
| Dr. Adam reports personal fees from BMS, grants and personal fees from MSD, personal fees from AstraZeneca, personal fees from Roche, during the conduct of the study; .   |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Adam 3